Neuromyelitis optica and neuromyelitis optica spectrum disorders

Close metadata

Recommended articles:

Biobanking in clinical trials involving multiple sclerosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):7-15

The diagnostic effectiveness of criteria for neuromyelitis optica spectrum disorders in the Russian clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):16-25

Adherence to treatment in the management of patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):26-32

Modern pathogenetic treatment of rare demyelinating diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):33-36

Optimal patient profile for ofatumumab treatment: analysis of Russian data from the Phase 3 study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):37-42

The effect of pregnancy on multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):43-49

Perspective directions in the treatment of polycystic ovary syndrome (literature review). Russian Journal of Human Reproduction. 2024;(3):94-104

Questionnaires for arm function assessment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):36-42

Features of primary forms of headache in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):70-73

Neurofilament light chain: a diagnostic potential for multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):115-119

The review is devoted to up-to-date data on epidemiology, aspects of the pathogenesis of neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD). The authors consider a role of myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) in the syndromes phenotypically similar to NMO and NMOSD. Special attention is drawn to the methods of MOG-IgG antibodies detection and indications for testing. The approaches and management for treatment and prevention of NMO relapses, risks of complications during pregnancy and immediately after delivery, as well as methods for their prevention and treatment, are described.

Keywords:

neuromyelitis optica

neuromyelitis optica spectrum disorders

aquaporin-4 immunoglobulin G antibodies

myelin oligodendrocyte glycoprotein immunoglobulin G antibodies

demyelinating diseases

treatment

Authors:

Simaniv T.O.

Neurology Research Center, Moscow

SPIN RSCI: 6243-8805
Scopus AuthorID: 56575192400
ORCID: 0000-0001-7256-2668

Vasilyev A.V.

Research Center of Neurology, Moscow, Russia

SPIN RSCI: 5640-9455
ORCID: 0000-0003-0599-2187

Askarova L.Sh.

FGBU "Nauchnyĭ tsentr nevrologii" RAN, Moskva

ORCID: 0000-0003-1606-7245

Zakharova M.N.

Research Center of Neurology, Moscow, Russia

SPIN RSCI: 4277-2860
Scopus AuthorID: 7006679636
ResearcherID: C-4611-2012
ORCID: 0000-0002-1072-9968

List of references:

Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489.
Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clinic Proceedings: Elsevier; 2017.
Simaniv TO, Vorob’yova AI, Smirnova NN, Zigangirova NN, Zaharova MN. Optikomielit i akvaporin-associirovannye sindromy. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2015;115(2-2):31-37. (In Russ.)
Fazio R, Radaelli M, Furlan R. Neuromyelitis optica: concepts in evolution. Journal of Neuroimmunology. 2011;231(1-2):100-104.
Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite M, Kleiter I, Chitnis T, Consortium GIC, Optica BfN. Demographic and clinical features of neuromyelitis optica: a review. Multiple Sclerosis Journal. 2015;21(7):845-853.
Etemadifar M, Nasr Z, Khalili B, Taherioun M, Vosoughi R. Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis. Multiple Sclerosis International. 2015;174720.
Asgari N, Lillevang S, Skejoe H, Falah M, Stenager E, Kyvik K. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76(18):1589-1595.
Cossburn M, Tackley G, Baker K, Ingram G, Burtonwood M, Malik G, Pickersgill T, te Water Naudé J, Robertson N. The prevalence of neuromyelitis optica in South East Wales. European Journal of Neurology. 2012;19(4):655-659.
Etemadifar M, Dashti M, Vosoughi R, Abtahi SH, Ramagopalan SV, Nasr Z. An epidemiological study of neuromyelitis optica in Isfahan. Multiple Sclerosis Journal. 2014;20(14):1920-1922.
Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, Das K, Boggild M. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. Journal of Neurology. 2013;260(8):2134-2137.
Cabre P, Gonzalez-Quevedo A, Lannuzel A, Bonnan M, Merle H, Olindo S, Chausson N, Lara-Rodriguez R, Smadja D, Cabrera-Gomez J. Descriptive epidemiology of neuromyelitis optica in the Caribbean basin. Revue Neurologique. 2009;165(8-9):676-683.
Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, Lara-Rodriguez R. An epidemiological study of neuromyelitis optica in Cuba. Journal of Neurology. 2009;256(1):35-44.
Pandit L, Kundapur R. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Multiple Sclerosis Journal. 2014;20(12):1651-1653.
Houzen H, Niino M, Hirotani M, Fukazawa T, Kikuchi S, Tanaka K, Sasaki H. Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. Journal of the Neurological Sciences. 2012;323(1-2):117-122.
Rivera JF, Kurtzke JF, Booth VA, Corona T. Characteristics of Devic’s disease (neuromyelitis optica) in Mexico. Journal of Neurology. 2008;255(5):710-715.
Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, Lennon VA, Lucchinetti CF, McKeon A, Matiello M. Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum. Annals of Neurology. 2016;79(5):775-783.
Jonsson DI, Sveinsson O, Hakim R, Brundin L. Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study. Neurology. 2019;93(2):181-189.
Miyamoto K, Fujihara K, Kira J-i, Kuriyama N, Matsui M, Tamakoshi A, Kusunoki S. Nationwide epidemiological study of neuromyelitis optica in Japan. J Neurol Neurosurg Psychiatry. 2018;89(6):667-668.
Kim S-H, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung H-P, Asgari N. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018;91(22):2089-2099.
Mori M, Kuwabara S, Paul F. Worldwide prevalence of neuromyelitis optica spectrum disorders. BMJ Publishing Group Ltd; 2018.
Ogawa K, Okuno T, Hosomichi K, Hosokawa A, Hirata J, Suzuki K, Sakaue S, Kinoshita M, Asano Y, Miyamoto K. Next-generation sequencing identifies contribution of both class I and II HLA genes on susceptibility of multiple sclerosis in Japanese. Journal of neuroinflammation. 2019;16(1):1-9.
Matsushita T, Matsuoka T, Isobe N, Kawano Y, Minohara M, Shi N, Nishimura Y, Ochi H, Kira J. Association of the HLA‐DPB1*0501 allele with anti‐aquaporin‐4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens. 2009;73(2):171-176.
Yoshimura S, Isobe N, Matsushita T, Yonekawa T, Masaki K, Sato S, Kawano Y, Kira J-I. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. J Neurol Neurosurg Psychiatry. 2013;84(1):29-34.
Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clinical & Experimental Immunology. 2014;176(2):149-164.
He D, Zhang A, Li Y, Cai G, Li Y, Guo S. Autoimmune aquaporin-4 induced damage beyond the central nervous system. Multiple sclerosis and related disorders. 2017;18:41-46.
Bennett JL, Owens GP. Neuromyelitis optica: deciphering a complex immune-mediated astrocytopathy. Journal of neuro-ophthalmology: the official journal of the North American Neuro-Ophthalmology Society. 2017;37(3):291.
Papadopoulos MC, Verkman A. Aquaporin 4 and neuromyelitis optica. The Lancet Neurology. 2012;11(6):535-544.
Spadaro M, Gerdes LA, Mayer MC, Ertl‐Wagner B, Laurent S, Krumbholz M, Breithaupt C, Högen T, Straube A, Giese A. Histopathology and clinical course of MOG‐antibody‐associated encephalomyelitis. Annals of Clinical and Translational Neurology. 2015;2(3):295-301.
Misu T, Höftberger R, Fujihara K, Wimmer I, Takai Y, Nishiyama S, Nakashima I, Konno H, Bradl M, Garzuly F. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathologica. 2013;125(6):815-827.
Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W, Wandinger K. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. Journal of the Neurological Sciences. 2010;291(1-2):52-56.
Waters P, McKeon A, Leite M, Rajasekharan S, Lennon VA, Villalobos A, Palace J, Mandrekar J, Vincent A, Bar-Or A. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78(9):665-671.
Jarius S, Metz I, König FB, Ruprecht K, Reindl M, Paul F, Brück W, Wildemann B. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Multiple Sclerosis Journal. 2016;22(12):1541-1549.
Waters PJ, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG, Wingerchuk DM. Evaluation of aquaporin‐4 antibody assays. Clinical and Experimental Neuroimmunology. 2014;5(3):290-303.
Simaniv TO, Vtorova NV, Vorob’yova AA, Zigangirova NA, Zaharova MN. Diagnosticheskoe znachenie antitel k akvaporinu-4 pri zabolevaniyah central’noj nervnoj sistemy. Nejrohimiya. 2014;31(3):246. (In Russ.)
Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume L-A, Hümmert MW. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. Journal of Neuroinflammation. 2016;13(1):279.
Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A. Restoring immune tolerance in neuromyelitis optica: Part I. Neurology-Neuroimmunology Neuroinflammation. 2016;3(5):e276.
Weber MS, Derfuss T, Metz I, Brück W. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Therapeutic Advances in Neurological Disorders. 2018;11:1756286418762083.
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, De Seze J, Fujihara K, Greenberg B, Jacob A. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.
Bourre B, Zéphir H, Ongagna J-C, Cordonnier C, Collongues N, Debette S, Fleury M-C, Outteryck O, Hannequin D, Vermersch P. Long-term follow-up of acute partial transverse myelitis. Archives of Neurology. 2012;69(3):357-362.
Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65(9):1479-1482.
Popescu BG, Lennon VA, Parisi JE, Howe CL, Weigand S, Cabrera-Gomez J, Newell K, Mandler R, Pittock SJ, Weinshenker BG. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011;76(14):1229-1237.
Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Archives of Neurology. 2006;63(3):390-396.
Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, Paul F, Jarius S, Aktas O, Elsone L. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Multiple Sclerosis Journal. 2014;20(7):843-847.
Bakulin IS, Simaniv TO, Konovalov RN, Zaharova MN. Porazhenie area postrema kak prichina neukrotimoj ikoty, toshnoty i rvoty pri zabolevaniyah optikomielitnogo spektra (nablyudenie iz praktiki). Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(10):20-23. (In Russ.)
Belova AN, Bojko AN, Belova EM. Diagnosticheskie kriterii optikomielit-associirovannyh rasstrojstv. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116(2):32-40. (In Russ.)
Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Archives of Neurology. 2006;63(7):964-968.
Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, Flanagan EP, McKeon A, Pittock SJ. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4—IgG in Patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmology. 2018;136(4):419-422.
Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A, Kneen R. Neuromyelitis optica spectrum disorders. Clinical Medicine. 2019;19(2):169-176.
Palace J, Lin D-Y, Zeng D, Majed M, Elsone L, Hamid S, Messina S, Misu T, Sagen J, Whittam D. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain. 2019;142(5):1310-1323.
Wang H, Wang C, Qiu W, Lu Z, Hu X, Wang K. Cerebrospinal fluid light and heavy neurofilaments in neuromyelitis optica. Neurochemistry International. 2013;63(8):805-808.
Kim W, Park MS, Lee SH, Kim S-H, Jung IJ, Takahashi T, Misu T, Fujihara K, Kim HJ. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Multiple Sclerosis Journal. 2010;16(10):1229-1236.
Huh S-Y, Min J-H, Kim W, Kim S-H, Kim HJ, Kim B-J, Kim BJ, Lee KH. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal. 2014;20(6):695-704.
Matthews L, Marasco R, Jenkinson M, Küker W, Luppe S, Leite MI, Giorgio A, De Stefano N, Robertson N, Johansen-Berg H. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013;80(14):1330-1337.
Nakamura M, Misu T, Fujihara K, Miyazawa I, Nakashima I, Takahashi T, Watanabe S, Itoyama Y. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Multiple Sclerosis Journal. 2009;15(6):695-700.
Pohl D, Alper G, Van Haren K, Kornberg AJ, Lucchinetti CF, Tenembaum S, Belman AL. Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome. Neurology. 2016;87(9-2):38-45.
Kim S-M, Woodhall MR, Kim J-S, Kim S-J, Park KS, Vincent A, Lee K-W, Waters P. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurology-Neuroimmunology Neuroinflammation. 2015;2(6):e163.
Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474-481.
Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. The Lancet Neurology. 2004;3(7):397-407.
Flanagan EP, Kaufmann TJ, Krecke KN, Aksamit AJ, Pittock SJ, Keegan BM, Giannini C, Weinshenker BG. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Annals of Neurology. 2016;79(3):437-447.
Wegener S, Linnebank M, Martin R, Valavanis A, Weller M. Clinically isolated neurosarcoidosis: a recommended diagnostic path. European Neurology. 2015;73(1-2):71-77.
Pittock SJ, Lennon VA, De Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zéphir H, Moder K, Weinshenker BG. Neuromyelitis optica and non—organ-specific autoimmunity. Archives of Neurology. 2008;65(1):78-83.
Adawi M, Bisharat B, Bowirrat A. Systemic Lupus Erythematosus (SLE) complicated by neuromyelitis optica (NMO—Devic’s Disease): clinic-pathological report and review of the literature. Clinical Medicine Insights: Case Reports. 2014;7:15177.
Piven’ VD, Krasnov VS, Novikova AS, Piven’ FM, Kushnir YaA, Totolyan NA. Zabolevanie spektra optikonejromielita: diagnostika i lechenie, opyt klinicheskih nablyudenij. Uchenye Zapiski SPbGMU im. I.P. Pavlova. 2018;25(3):34-39. (In Russ.)
Sellner J, Boggild M, Clanet M, Hintzen R, Illes Z, Montalban X, Du Pasquier R, Polman C, Sorensen P, Hemmer B. EFNS guidelines on diagnosis and management of neuromyelitis optica. European Journal of Neurology. 2010;17(8):1019-1032.
Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Multiple Sclerosis Journal. 2016;22(2):185-192.
Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Annals of Neurology. 2016;79(2):206-216.
Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Annals of Neurology. 1999;46(6):878-886.
Bonnan M, Valentino R, Debeugny S, Merle H, Fergé J-L, Mehdaoui H, Cabre P. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346-351.
Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). Journal of Neurology. 2014;261(1):1-16.
Collongues N, Ayme-Dietrich E, Monassier L, de Seze J. Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. Drugs. 2019;79(2):125-142.
Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51(4):1219-1220.
Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, Fujihara K, De Seze J. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2013;84(8):922-930.
Borisow N, Mori M, Kuwabara S, Paul F. Diagnosis and treatment of NMO spectrum disorder and MOG2 encephalomyelitis. Frontiers in Neurology. 2018;9:888.
Qiu W, Kermode AG, Li R, Dai Y, Wang Y, Wang J, Zhong X, Li C, Lu Z, Hu X. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. Journal of Clinical Neuroscience. 2015;22(7):1178-1182.
Patt H, Bandgar T, Lila A, Shah N. Management issues with exogenous steroid therapy. Indian Journal of Endocrinology and Metabolism. 2013;17(suppl 3):S612.
Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Vukusic S, Zephir H. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Revue Neurologique. 2018;174(4):255-264.
Cohen M, Romero G, Bas J, Ticchioni M, Rosenthal M, Lacroix R, Brunet C, Rico A, Pelletier J, Audoin B. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. Journal of the Neurological Sciences. 2017;373:335-338.
Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurology. 2016;73(11):1342-1348.
Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. Journal of Neurology. 2017;264(9):2003-2009.
Zhang M, Zhang C, Bai P, Xue H, Wang G. Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study. Acta Neurologica Belgica. 2017;117(3):695-702.
Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche J-P, Labauge P. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal. 2017;23(10):1377-1384.
Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Archives of Neurology. 2009;66(9):1128-1133.
Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurology. 2014;71(3):324-330.
Viswanathan S, Wong AH, Quek AM, Yuki N. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. Journal of Neuroimmunology. 2015;282:92-96.
Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry. 2013;84(5):511-516. https://doi.org/10.1136/jnnp-2012-303121
Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree BA, de Seze J, Flor A, Fujihara K, Greenberg B, Higashi S, Holt W, Khan O, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter S, Villoslada P, Walton MK, Wasiewski W, Wingerchuk DM, Yeaman MR. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology. 2015;84(17):1805-1815. https://doi.org/10.1212/wnl.0000000000001520
Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. The New England Journal of Medicine. 2019;381(7):614-625. https://doi.org/10.1056/NEJMoa1900866
Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Haramura M. Efficacy of satralizumab (SA237) in subgroups of patients in SAkuraSky: a Phase III double-blind, placebo-controlled, add-on study in patients with neuromyelitis optica spectrum disorder (NMOSD) (S43.008). AAN Enterprises; 2019.
Cree B, Bennett J, Kim HJ, Weinshenker B, Pittock S, Wingerchuk D, Fujihara K, Paul F, Cutter G, Marignier R. A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adult Subjects with Neuromyelitis Optica Spectrum Disorders — Top line efficacy and safety results (Plen02. 001). AAN Enterprises; 2019.
Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, Papadopoulos MC, Bennett JL, Verkman A. Anti-Aquaporin‐4 monoclonal antibody blocker therapy for neuromyelitis optica. Annals of Neurology. 2012;71(3):314-322.
Kira J-i. Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others? Multiple Sclerosis Journal. 2017;23(9):1300-1302.
Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung H-P, Paul F, Aktas O, Group NOS. Failure of natalizumab to prevent relapses in neuromyelitis optica. Archives of Neurology. 2012;69(2):239-245.
Gelfand JM, Cotter J, Klingman J, Huang EJ, Cree BA. Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurology-Neuroimmunology Neuroinflammation. 2014;1(3):e34.
Palace J, Leite MI, Nairne A, Vincent A. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Archives of Neurology. 2010;67(8):1016-1017.
Min J-H, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal. 2012;18(1):113-115.
Yamout BI, Beaini S, Zeineddine MM, Akkawi N. Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal. 2017;23(9):1297-1300.
Borisow N, Kleiter I, Gahlen A, Fischer K, Wernecke K-D, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T. Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal. 2017;23(8):1092-1103.
Nour MM, Nakashima I, Coutinho E, Woodhall M, Sousa F, Revis J, Takai Y, George J, Kitley J, Santos ME. Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology. 2016;86(1):79-87.
Saadoun S, Waters P, Leite MI, Bennett JL, Vincent A, Papadopoulos MC. Neuromyelitis optica IgG causes placental inflammation and fetal death. The Journal of Immunology. 2013;191(6):2999-3005.
Shosha E, Pittock SJ, Flanagan E, Weinshenker BG. Neuromyelitis optica spectrum disorders and pregnancy: interactions and management. Multiple Sclerosis Journal. 2017;23(14):1808-1817.
Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017;89(22):2238-2244.
Bourre B, Marignier R, Zephir H, Papeix C, Brassat D, Castelnovo G, Collongues N, Vukusic S, Labauge P, Outteryck O. Neuromyelitis optica and pregnancy. Neurology. 2012;78(12):875-879.
Shimizu Y, Fujihara K, Ohashi T, Nakashima I, Yokoyama K, Ikeguch R, Takahashi T, Misu T, Shimizu S, Aoki M. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal. 2016;22(11):1413-1420.
Martínez-Sánchez N, Pérez-Pinto S, Robles-Marhuenda Á, Arnalich-Fernández F, Cameán MM, Zalvide EH, Bartha JL. Obstetric and perinatal outcome in anti-Ro/SSA-positive pregnant women: a prospective cohort study. Immunologic research. 2017;65(2):487-494.
Park‐Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta‐analysis of epidemiological studies. Teratology. 2000;62(6):385-392.
Cox JL, Koepsell SA, Shunkwiler SM. Therapeutic plasma exchange and pregnancy: a case report and guidelines for performing plasma exchange in a pregnant patient. Journal of clinical apheresis. 2017;32(3):191-195.
Alami Z, Agier MS, Ahid S, Vial T, Dautriche A, Lagarce L, Toutain A, Cherrah Y, Jonville-Bera A-P. Pregnancy outcome following in utero exposure to azathioprine: A French comparative observational study. Therapies. 2018;73(3):199-207.
Pellkofer H, Suessmair C, Schulze A, Hohlfeld R, Kuempfel T. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Multiple Sclerosis Journal. 2009;15(8):1006-1008.
Borisow N, Hellwig K, Paul F. Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies. EPMA Journal. 2018;9(3):249-256.
Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Current treatment options in neurology. 2016;18(1):2.

Close metadata